<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The activating mutation of JAK2, V617F, has been found as a frequent mutation in myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPNs), including <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), essential <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> (ET), and primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (PMF) </plain></SENT>
<SENT sid="1" pm="."><plain>This mutation is observed not only in MPNs, but also in <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>We report a case of myeloid <z:hpo ids='HP_0100242'>sarcoma</z:hpo> and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, followed by <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>, with detection of homozygous JAK2 V617F mutation </plain></SENT>
<SENT sid="3" pm="."><plain>This report describes the first case of myeloid <z:hpo ids='HP_0100242'>sarcoma</z:hpo> with JAK2 V617F mutation and implication of its progression to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>